MARKET

ONVO

ONVO

Organovo Holding
NASDAQ
1.100
+0.070
+6.80%
Opening 15:12 05/20 EDT
OPEN
1.050
PREV CLOSE
1.030
HIGH
1.100
LOW
1.030
VOLUME
109.96K
TURNOVER
0
52 WEEK HIGH
2.050
52 WEEK LOW
0.8500
MARKET CAP
14.29M
P/E (TTM)
-0.5066
1D
5D
1M
3M
1Y
5Y
Organovo Granted U.S. Patent #11982668: Use Of Engineered Renal Tissues In Assays
Benzinga · 6d ago
Weekly Report: what happened at ONVO last week (0506-0510)?
Weekly Report · 05/13 11:02
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
AppLovin Corporation shares jumped 14.8% in today's pre-market trading. The company reported better-than-expected first-quarter financial results. Pop Culture Group Co., Ltd. Shares rose 60.3% to $2.71 in pre- market trading.
Benzinga · 05/09 12:13
Organovo Holdings, Inc. Announces Pricing Of $5.25M Public Offering Of 6,562,500 Shares Of Common Stock And Common Warrants At A Combined Price Of $0.80
Organovo Holdings, Inc. Announced the pricing of a public offering of 6,562,500 shares of its common stock. The gross proceeds from the offering are expected to be $5.25 million. The offering is expected to close in May 2024. Organovo is a clinical stage biotechnology company focused on developing novel treatment approaches.
Benzinga · 05/09 00:09
*Organovo Holdings' Offering of 6.6 Million Shares and Warrants Prices at 80 Cents a Share and Warrant
Dow Jones · 05/09 00:03
*Organovo Holdings Announces Pricing of $5.25M Public Offering
Dow Jones · 05/09 00:02
ORGANOVO HOLDINGS, INC. ANNOUNCES PRICING OF $5.25 MILLION PUBLIC OFFERING
Reuters · 05/09 00:00
Press Release: Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
Organovo Holdings, Inc. Announces Pricing of $5.25 million public offering. Organovo is a clinical stage biotechnology company focused on developing novel treatment approaches in three-dimensional human tissues. The company's lead molecule, FXR314, is on the path for Phase 2 in inflammatory bowel disease.
Dow Jones · 05/09 00:00
More
About ONVO
Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.

Webull offers Organovo Holdings Inc stock information, including NASDAQ: ONVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONVO stock methods without spending real money on the virtual paper trading platform.